Wiesner-Kiełczewska Agnieszka, Zagrodzki Paweł, Paśko Paweł
Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, św. Łazarza 16, 31-530, Kraków, Poland.
Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
Clin Pharmacokinet. 2025 May 10. doi: 10.1007/s40262-025-01511-6.
Managing food-drug interactions may help to optimize the efficacy and safety of antifungal therapy. This systematic review followed Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines to evaluate how food, beverages, antacids, and mineral supplements influence the pharmacokinetic (PK) parameters or pharmacokinetic/pharmacodynamic (PK/PD) indices of 14 orally administered antifungal drugs.
We considered all studies evaluating the effects of food, beverages, antacids, and mineral supplements on PK parameters and PK/PD indices of oral antifungal drugs for inclusion. We excluded in vitro, in silico, animal studies, reviews, and alcohol-related investigations. Searches were conducted in Medline (via PubMed), Embase, and Cochrane Library from database inception to June 2024. We evaluated the risk of bias using the National Institutes of Health (NIH) tool for before-after studies and the Cochrane tool for parallel and cross-over trials. We performed meta-analyses when two or more studies with comparable designs were available; otherwise, results were summarized qualitatively.
The review included 73 studies from 68 reports. Only studies investigating the effect of dietary interactions on PK parameters were found. Meta-analyses were conducted for seven antifungal drugs, while qualitative synthesis covered the remaining drugs. Open-label, cross-over studies accounted for 58% of trials, aligning with Food and Drug Administration (FDA) recommendations. A high risk of bias appeared in 33% of studies, while only 7% showed low risk. Among 11 antifungals with food-effect data, seven (64%) exhibited clinically important interactions. High positive food effects (area under the concentration-time curve (AUC) or peak serum concentration (C) increased by > 45%) were seen for griseofulvin, itraconazole capsules and tablets (except rice-based meals), and posaconazole immediate-release tablets and suspension. A moderate positive impact of high-fat meals (AUC or C increased in the range of 35-45%) occurred for ibrexafungerp and oteseconazole. A high negative food effect was observed on the absorption of voriconazole and itraconazole oral suspension or super bioavailable (SUBA) capsules (AUC or C decreased by > 40%). Antacids strongly reduced itraconazole and ketoconazole absorption, while nutritional supplements improved posaconazole bioavailability. Acidic beverages such as Coca Cola substantially enhanced the absorption of itraconazole, ketoconazole, and posaconazole, whereas orange juice significantly reduced itraconazole bioavailability.
Interactions were influenced by such factors as drug physicochemical properties, type of dietary intervention, drug formulation, and patient characteristics. Although the review largely filled the existing gaps in recommendations, we judged the overall quality of evidence as low owing to outdated studies, methodological inconsistencies, and uneven data availability. Further research involving PK/PD indices is needed to link the postprandial changes in the bioavailability of antifungal drugs with their clinical efficacy.
The protocol of the systematic review was registered in March 2024 in the Open Science Framework (OSF) Registries ( https://doi.org/10.17605/OSF.IO/HAVK9 ).
管理食物-药物相互作用可能有助于优化抗真菌治疗的疗效和安全性。本系统评价遵循系统评价与Meta分析的首选报告项目(PRISMA)指南,以评估食物、饮料、抗酸剂和矿物质补充剂如何影响14种口服抗真菌药物的药代动力学(PK)参数或药代动力学/药效学(PK/PD)指标。
我们纳入所有评估食物、饮料、抗酸剂和矿物质补充剂对口服抗真菌药物PK参数和PK/PD指标影响的研究。我们排除了体外、计算机模拟、动物研究、综述以及与酒精相关的研究。从数据库建立至2024年6月在Medline(通过PubMed)、Embase和Cochrane图书馆进行检索。我们使用美国国立卫生研究院(NIH)的前后对照研究工具和Cochrane的平行和交叉试验工具评估偏倚风险。当有两项或更多设计可比的研究时,我们进行Meta分析;否则,对结果进行定性总结。
该评价纳入了68篇报告中的73项研究。仅发现了研究饮食相互作用对PK参数影响的研究。对7种抗真菌药物进行了Meta分析,其余药物进行了定性综合分析。开放标签的交叉研究占试验的58%,符合美国食品药品监督管理局(FDA)的建议。33%的研究存在高偏倚风险,只有7%的研究显示低偏倚风险。在有食物效应数据的11种抗真菌药物中,7种(64%)表现出具有临床意义的相互作用。灰黄霉素、伊曲康唑胶囊和片剂(基于米饭的餐食除外)、泊沙康唑速释片和混悬液出现高阳性食物效应(浓度-时间曲线下面积(AUC)或血清峰浓度(C)增加>45%)。高脂餐对ibrexafungerp和oteseconazole有中度阳性影响(AUC或C增加35%-45%)。观察到伏立康唑以及伊曲康唑口服混悬液或超生物利用度(SUBA)胶囊的吸收有高阴性食物效应(AUC或C降低>40%)。抗酸剂强烈降低伊曲康唑和酮康唑的吸收,而营养补充剂提高泊沙康唑的生物利用度。酸性饮料如可口可乐显著增强伊曲康唑、酮康唑和泊沙康唑的吸收,而橙汁显著降低伊曲康唑的生物利用度。
相互作用受药物理化性质、饮食干预类型、药物剂型和患者特征等因素影响。尽管该评价在很大程度上填补了现有建议中的空白,但由于研究过时、方法不一致以及数据可用性不均衡,我们判定证据的总体质量较低。需要进一步开展涉及PK/PD指标的研究,以将抗真菌药物餐后生物利用度的变化与其临床疗效联系起来。
该系统评价的方案于2024年3月在开放科学框架(OSF)注册中心(https://doi.org/10.17605/OSF.IO/HAVK9)注册。